241 391

Cited 0 times in

The optimal selection of radiotherapy treatment for hepatocellular carcinoma.

DC Field Value Language
dc.contributor.author성진실-
dc.contributor.author이익재-
dc.date.accessioned2014-12-19T16:51:29Z-
dc.date.available2014-12-19T16:51:29Z-
dc.date.issued2012-
dc.identifier.issn1976-2283-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/90326-
dc.description.abstractThe majority of patients who present with hepatocellular carcinoma (HCC) are already at an advanced stage, and the tumors are unresectable. Radiotherapy (RT) technology can safely provide focused high-dose irradiation to these patients. A wide spectrum of RT technologiesis currently available, including internal RT consisting of Yttrium-90 ((90)Y), Iodine-131 ((131)I) anti-ferritin antibody and Homium-199 ((199)Ho) and external RT, such as three-dimensional conformal RT, intensity-modulated RT, helical tomotherapy, stereotactic body RT, and image-guided RT. However, it may be difficult for physicians to understand all of the available options and to select the optimal RT treatment. Physicians frequently query radiation oncologists on the practical indications of RT for managing patients with HCC. According to the Korean Liver Cancer Study Group practice guidelines, RT is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, a Child-Pugh class A or B, and tumors that occupy less than two-thirds of the liver with level II evidence. In this review, we discuss the application of various RT modalities based on disease status and the detailed indications for RT according to the Barcelona Clinic Liver Cancer staging system.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfGUT AND LIVER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleThe optimal selection of radiotherapy treatment for hepatocellular carcinoma.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학)-
dc.contributor.googleauthorIk Jae Lee-
dc.contributor.googleauthorJinsil Seong-
dc.identifier.doi22570744-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01956-
dc.contributor.localIdA03055-
dc.relation.journalcodeJ00954-
dc.identifier.eissn2005-1212-
dc.identifier.pmid22570744-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordRadiotherapy-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.alternativeNameLee, Ik Jae-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.contributor.affiliatedAuthorLee, Ik Jae-
dc.citation.volume6-
dc.citation.number2-
dc.citation.startPage139-
dc.citation.endPage148-
dc.identifier.bibliographicCitationGUT AND LIVER, Vol.6(2) : 139-148, 2012-
dc.identifier.rimsid34144-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.